Swiss National Bank boosted its holdings in shares of Invitae Co. (NYSE:NVTA – Get Rating) by 5.2% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 506,600 shares of the medical research company's stock after buying an additional 24,900 shares during the period. Swiss National Bank owned approximately 0.22% of Invitae worth $1,236,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also recently bought and sold shares of the company. Operose Advisors LLC acquired a new position in Invitae in the 1st quarter worth about $32,000. Cetera Investment Advisers acquired a new position in Invitae in the 1st quarter worth about $82,000. SG Americas Securities LLC increased its position in Invitae by 42.1% in the 1st quarter. SG Americas Securities LLC now owns 10,341 shares of the medical research company's stock worth $82,000 after purchasing an additional 3,062 shares during the last quarter. MQS Management LLC acquired a new position in Invitae in the 2nd quarter worth about $28,000. Finally, Oppenheimer & Co. Inc. acquired a new position in Invitae in the 2nd quarter worth about $30,000. 88.27% of the stock is owned by institutional investors and hedge funds.

Invitae Price Performance

Shares of NYSE:NVTA opened at $2.97 on Friday. The business has a 50 day moving average price of $2.57 and a 200 day moving average price of $2.89. Invitae Co. has a twelve month low of $1.83 and a twelve month high of $18.44. The company has a market cap of $721.40 million, a price-to-earnings ratio of -0.21 and a beta of 1.59. The company has a quick ratio of 6.18, a current ratio of 6.44 and a debt-to-equity ratio of 10.03.

Wall Street Analysts Forecast Growth

NVTA has been the topic of several research reports. Cowen upped their target price on Invitae to $2.80 in a research report on Tuesday, November 15th. SVB Leerink increased their price objective on Invitae from $2.50 to $3.00 and gave the company a "market perform" rating in a report on Wednesday, November 9th. StockNews.com raised Invitae to a "sell" rating in a report on Friday, November 18th. JPMorgan Chase & Co. lowered Invitae from a "neutral" rating to an "underweight" rating in a report on Wednesday, August 10th. Finally, William Blair reissued a "market perform" rating on shares of Invitae in a report on Tuesday, November 8th. Four equities research analysts have rated the stock with a sell rating and nine have assigned a hold rating to the company. Based on data from MarketBeat.com, Invitae currently has a consensus rating of "Hold" and a consensus price target of $8.04.

About Invitae

(Get Rating)

Invitae Corporation, a medical genetics company, integrates genetic information into mainstream medicine to improve healthcare of people in the United States, Canada, and internationally. The company offers genetic tests in various clinical areas, including hereditary cancer, cardiology, neurology, pediatrics, oncology, metabolic conditions, and rare diseases; digital health solutions; and health data services.

See Also

• Get a free copy of the StockNews.com research report on Invitae (NVTA)
• Ford Revving Up Production Of EV Power Units At U.K. Plant
• Are the Short Sellers Still Right About Mullen Automotive stock?
• La-Z-Boy Reclines To More Comfortable Levels
• Is Apple Going To Rally Into Year End?
• Is The Recovery Rally Here For SoFi?

Want to see what other hedge funds are holding NVTA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Invitae Co. (NYSE:NVTA – Get Rating).

Receive News & Ratings for Invitae Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Invitae and related companies with MarketBeat.com's FREE daily email newsletter.